Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEB-TACE followed by 125I seed brachytherapy for HCC with type I-II PVTT
ChiCTR2200061945Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- May 2022
- Modality
- Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of CalliSpheres in hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Progression-free survival. Planned start May 2022; status: not yet recruiting.
02
Drugs
CalliSpheres
03
Conditions
hepatocellular carcinoma (HCC)portal vein tumor thrombosis (PVTT)
Beyond the preview
Go deeper on ChiCTR2200061945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061945.